Cargando…

The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study

BACKGROUND: There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17α-estradiol (Ell-Cra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jae-Hong, Lee, Sung Yul, Lee, Hae-Jin, Yoon, Na-Young, Lee, Won-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Dermatological Association; The Korean Society for Investigative Dermatology 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412238/
https://www.ncbi.nlm.nih.gov/pubmed/22879713
http://dx.doi.org/10.5021/ad.2012.24.3.295
_version_ 1782239942021218304
author Kim, Jae-Hong
Lee, Sung Yul
Lee, Hae-Jin
Yoon, Na-Young
Lee, Won-Soo
author_facet Kim, Jae-Hong
Lee, Sung Yul
Lee, Hae-Jin
Yoon, Na-Young
Lee, Won-Soo
author_sort Kim, Jae-Hong
collection PubMed
description BACKGROUND: There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17α-estradiol (Ell-Cranell® alpha 0.025%) solution to Korean female patients with FPHL. OBJECTIVE: This study was designed to examine the efficacy and safety of Ell-Cranell® alpha 0.025% solution in Korean female patients with FPHL. METHODS: A total of 53 women, 18 to 55 years old, applied topical Ell-Cranell® alpha 0.025% solution once daily for 8 months. Efficacy was evaluated by the change of hair counts and diameter, subjective assessment, and photographic assessment by investigators. RESULTS: Hair counts and diameter from baseline to 4 and 8 months after treatment increased in treated patients and these changes were statistically significant (p<0.0001). 17α-estradiol (Ell-Cranell® alpha 0.025%) solution showed significant improvement by subjective self-assessment and by investigator photographic assessment. Ell-Cranell® alpha 0.025% solution was well tolerated over 8-months period. CONCLUSION: This study showed that Ell-Cranell® alpha 0.025% solution is a safe and effective agent for Korean women with FPHL.
format Online
Article
Text
id pubmed-3412238
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Korean Dermatological Association; The Korean Society for Investigative Dermatology
record_format MEDLINE/PubMed
spelling pubmed-34122382012-08-09 The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study Kim, Jae-Hong Lee, Sung Yul Lee, Hae-Jin Yoon, Na-Young Lee, Won-Soo Ann Dermatol Original Article BACKGROUND: There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17α-estradiol (Ell-Cranell® alpha 0.025%) solution to Korean female patients with FPHL. OBJECTIVE: This study was designed to examine the efficacy and safety of Ell-Cranell® alpha 0.025% solution in Korean female patients with FPHL. METHODS: A total of 53 women, 18 to 55 years old, applied topical Ell-Cranell® alpha 0.025% solution once daily for 8 months. Efficacy was evaluated by the change of hair counts and diameter, subjective assessment, and photographic assessment by investigators. RESULTS: Hair counts and diameter from baseline to 4 and 8 months after treatment increased in treated patients and these changes were statistically significant (p<0.0001). 17α-estradiol (Ell-Cranell® alpha 0.025%) solution showed significant improvement by subjective self-assessment and by investigator photographic assessment. Ell-Cranell® alpha 0.025% solution was well tolerated over 8-months period. CONCLUSION: This study showed that Ell-Cranell® alpha 0.025% solution is a safe and effective agent for Korean women with FPHL. Korean Dermatological Association; The Korean Society for Investigative Dermatology 2012-08 2012-07-25 /pmc/articles/PMC3412238/ /pubmed/22879713 http://dx.doi.org/10.5021/ad.2012.24.3.295 Text en Copyright © 2012 The Korean Dermatological Association and The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Jae-Hong
Lee, Sung Yul
Lee, Hae-Jin
Yoon, Na-Young
Lee, Won-Soo
The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
title The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
title_full The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
title_fullStr The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
title_full_unstemmed The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
title_short The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
title_sort efficacy and safety of 17α-estradiol (ell-cranell® alpha 0.025%) solution on female pattern hair loss: single center, open-label, non-comparative, phase iv study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412238/
https://www.ncbi.nlm.nih.gov/pubmed/22879713
http://dx.doi.org/10.5021/ad.2012.24.3.295
work_keys_str_mv AT kimjaehong theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT leesungyul theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT leehaejin theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT yoonnayoung theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT leewonsoo theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT kimjaehong efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT leesungyul efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT leehaejin efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT yoonnayoung efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy
AT leewonsoo efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy